A Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With Chronic Idiopathic Thrombocytopenic Purpura (ITP) Who Completed 28 Days of Study Treatment in Protocol 501-CL-003

Inclusion Criteria:

1. Patients who completed 28 days of study treatment in Protocol 501-CL-003.

2. No significant safety or tolerability concerns from the patient's participation of
Protocol 501-CL-003 as determined by the Investigator.

3. Received medical monitor approval for enrollment into this study.

4. Patients receiving maintenance corticosteroids may be enrolled, as long as the
corticosteroids have been administered at a stable dose and the Investigator does not
foresee the need to change the steroid dose during study participation. Patients
should remain on this stable corticosteroid dose during study participation.

5. Women of child-bearing potential must have a negative serum pregnancy test at the Day
28 assessment in Protocol 501-CL-003. (Childbearing potential is defined as any woman
who has not been surgically sterilized and is pre-menopausal or peri-menopausal i.e.,
any menstrual flow within 12 months of Screening Visit A for Protocol 501-CL-003).

6. Women of child-bearing potential must agree to practice a medically approved form of
contraception (one of the following must be used: condoms (male or female) with a
spermicidal agent, diaphragm or cervical cap with a spermicidal agent, IUD,hormonal
contraception, abstinence).

7. Willing and able to provide written informed consent.

Exclusion Criteria:

1. Women who are pregnant and/or lactating.

2. Use of the following drugs or treatments:

- Rituximab

- Azathioprine, Cyclosporine A, or other immunosuppressant therapy

- Aspirin, Aspirin-containing compounds, Salicylates,Anticoagulants, Non-steroidal
anti-inflammatory drugs(NSAIDs)(including Cyclooxygenase-2 [COX-2] specific
NSAIDs), clopidogrel; ticlopidine; and any drugs that affect platelet function.

- Danazol

- Rh0(D) immune globulin (WinRho®) or intravenous immunoglobulin (IVIG).

3. Inability to comply with protocol requirements or give informed consent, as
determined by the Investigator.

For more information regarding inclusion/exclusion criteria, please see record for AKR
501-CL-003 Protocol.